Biosimilar Contract Manufacturing Market Share

ID: MRFR/Pharma/10382-HCR

128 Pages

Rahul Gotadki

February 2026

Biosimilar Contract Manufacturing Market Research Report Information By Product (Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins), By Production Technology (Mammalian and Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Biosimilar Contract Manufacturing Market Infographic

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Share

Biosimilar Contract Manufacturing Market Share Analysis

The Biosimilar Contract Manufacturing Market within complex pharmaceutical industry intricacies has strategic tactics applied to secure market share and gain a competitive advantage. A key strategy also revolves around cost efficiency and scalability. Contract manufacturing organizations (CMOs) offering biosimilar production services prioritize providing economical options without compromising on quality. Through improving the manufacturing process and leveraging economies of scale, such firms therefore become attractive partners for pharma manufacturers intending to bring biosimilars into the market at lower costs.

In addition, customer-centric strategies have remained instrumental in the Biosimilar Contract Manufacturing Market. Given that different pharmaceutical companies have different needs, CMOs design their offerings to address those specific requirements. Customization, ability to be adaptable in manufacturing and compliance to regulations are important aspects that lead to sales increase. This strategy ensures long-term collaborations as well as attracts new clients from whom they can get customized solutions specifically tailored for their own biosimilar products’ peculiarities.

Moreover, strategic partnerships and collaborations are essential for increasing market share in the Biosimilar Contract Manufacturing Market. Biotechnological firms, research institutions and drug manufacturers often join hands with CMOs in order to pool resources together, share knowledge and broaden market coverage. Their credibility is improved by associating with reputable partners because it guarantees them access to a larger pool of customers. By so doing, these companies can easily enter new markets by using the strong points of their collaborators thus enhancing their cumulative market share.

Furthermore, geographical expansion is an important aspect of market share positioning within the Biosimilar Contract Manufacturing Market. Thusly, CMOs focus on regions where growth for low price biosimilars is being witnessed. The creation of a strong presence in major geography allows CMOs to venture into emerging markets as well as benefit from rising demand for biosimilars locally produced ones since this gives room for savings on transportation expenses while ensuring faster response times thus reinforcing positions held by CMO’s.

Finally, technology and infrastructure investment is a key strategy employed by CMOs in the Biosimilar Contract Manufacturing Market. This means that these companies maintain their competitiveness by providing cutting-edge facilities and services as they keep pace with technological developments in bioprocessing and manufacturing technologies. Investments into current generation manufacturing sites, analytical capabilities, and quality control systems are aimed at not only improving performance but also enabling the CMO to be perceived as having superior biosimilar manufacturing solutions.

Most importantly, adherence to regulatory standards is crucial in the Biosimilar Contract Manufacturing Market. In order to address this issue of strict regulations for biosimilar production process, pharma firms prefer dealing with CMOs who adhere to global quality standards. A CMO that obtains all necessary certificates and complies with existing policies thereby becomes an essential partner within complex biosimilar development environment. By doing so, trust among customers is built and hence expansion of markets can be facilitated since different regions have varied requirements on regulation.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the current valuation of the Biosimilar Contract Manufacturing Market?

As of 2024, the market valuation was 7.729 USD Billion.

What is the projected market size for the Biosimilar Contract Manufacturing Market by 2035?

The market is projected to reach 51.9 USD Billion by 2035.

What is the expected CAGR for the Biosimilar Contract Manufacturing Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 18.9%.

Which companies are considered key players in the Biosimilar Contract Manufacturing Market?

Key players include Samsung Biologics, Lonza Group, Boehringer Ingelheim, and Fujifilm Diosynth Biotechnologies.

What are the main product segments in the Biosimilar Contract Manufacturing Market?

The main product segments include Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins, each valued at approximately 3.8645 USD Billion.

How does the production technology segment break down in terms of valuation?

The production technology segment is valued at 4.5 USD Billion for Mammalian and 3.229 USD Billion for Non-Mammalian technologies.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future analysis, the Biosimilar Contract Manufacturing Market Size was estimated at 7.729 USD Billion in 2024. The Biosimilar Contract Manufacturing industry is projected to grow from 9.189 USD Billion in 2025 to 51.9 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 18.9% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Biosimilar Contract Manufacturing Market is poised for substantial growth driven by technological advancements and increasing demand for cost-effective solutions.

The market is witnessing a rising demand for cost-effective biosimilar solutions, particularly in North America, which remains the largest market. Technological advancements in manufacturing processes are enhancing the efficiency and quality of biosimilar production. Collaborative partnerships among key stakeholders are becoming increasingly prevalent, especially in the Asia-Pacific region, which is the fastest-growing market. The increasing prevalence of chronic diseases and regulatory support are major drivers propelling the growth of recombinant glycosylated proteins and mammalian segments.

Biosimilar Contract Manufacturing Market

CAGR

18.9%

Market Size & Forecast

2024 Market Size	7.729 (USD Billion)
2035 Market Size	51.9 (USD Billion)
CAGR (2025 - 2035)	18.9%
Largest Regional Market Share in 2024	Europe

Major Players

<a href="https://samsungbiologics.com/services/biopharma-quality">Samsung Biologics</a> (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Roche (CH), Amgen (US), Sandoz (CH)

Market Trends

The Biosimilar Contract Manufacturing Market is currently experiencing a notable evolution, driven by the increasing demand for cost-effective alternatives to expensive biologics. This market appears to be expanding as pharmaceutical companies seek to leverage contract manufacturing organizations (CMOs) to enhance their production capabilities. The growing emphasis on reducing healthcare costs, coupled with the rising prevalence of chronic diseases, suggests that the market is poised for further growth. Additionally, regulatory frameworks are becoming more favorable, which may encourage the development and commercialization of biosimilars. As a result, stakeholders are likely to invest in advanced technologies and processes to ensure compliance and maintain product quality. Moreover, the competitive landscape of the Biosimilar Contract Manufacturing Market is shifting, with numerous players entering the field. This influx of new entrants could lead to increased innovation and collaboration among industry participants. Partnerships between established pharmaceutical companies and emerging biosimilar manufacturers may facilitate knowledge transfer and resource sharing, potentially enhancing the overall efficiency of production. Furthermore, the focus on sustainability and environmentally friendly practices is becoming more pronounced, indicating that future developments in this market may also prioritize eco-conscious manufacturing processes. Overall, the Biosimilar Contract Manufacturing Market appears to be on a trajectory of growth, driven by various factors that align with the evolving healthcare landscape.

Rising Demand for Cost-Effective Solutions

The ongoing quest for affordable healthcare options is propelling the Biosimilar Contract Manufacturing Market forward. As healthcare costs continue to escalate, stakeholders are increasingly turning to biosimilars as viable alternatives to traditional biologics. This trend indicates a shift in focus towards more economical solutions, which may enhance patient access to essential therapies.

Advancements in Technology

Technological innovations are playing a crucial role in shaping the Biosimilar Contract Manufacturing Market. The integration of cutting-edge manufacturing techniques and automation is likely to improve production efficiency and product quality. This trend suggests that companies are investing in state-of-the-art facilities to meet the growing demand for biosimilars.

Collaborative Partnerships

The formation of strategic alliances among pharmaceutical companies and contract manufacturers is becoming more prevalent in the Biosimilar Contract Manufacturing Market. These collaborations may facilitate knowledge sharing and resource optimization, potentially leading to accelerated development timelines and enhanced market competitiveness.

Biosimilar Contract Manufacturing Market Market Drivers

Cost-Effectiveness of Biosimilars

The cost-effectiveness of biosimilars compared to their reference biologics is a significant driver for the Biosimilar Contract Manufacturing Market. As healthcare costs continue to rise, payers and patients are increasingly seeking more affordable treatment options. Biosimilars offer a viable solution, often priced 20-30% lower than their reference products. This price differential not only makes biosimilars more accessible to patients but also encourages healthcare providers to prescribe them. Consequently, pharmaceutical companies are motivated to engage in contract manufacturing to produce biosimilars, thereby expanding their portfolios and meeting market demand. The Biosimilar Contract Manufacturing Market is thus likely to thrive as the emphasis on cost-effective healthcare solutions intensifies.

Regulatory Support and Frameworks

The establishment of supportive regulatory frameworks for biosimilars is a crucial factor influencing the Biosimilar Contract Manufacturing Market. Regulatory agencies are increasingly recognizing the importance of biosimilars in enhancing patient access to essential medications. For instance, streamlined approval processes and guidelines for biosimilar development have been implemented in various regions, facilitating faster market entry. This regulatory support not only encourages pharmaceutical companies to explore biosimilar options but also enhances the confidence of contract manufacturers in investing in biosimilar production capabilities. As a result, the Biosimilar Contract Manufacturing Market is likely to experience accelerated growth, driven by the favorable regulatory landscape that promotes the development and commercialization of biosimilars.

Growing Focus on Personalized Medicine

The increasing emphasis on personalized medicine is shaping the Biosimilar Contract Manufacturing Market. As healthcare shifts towards tailored treatment approaches, the demand for biosimilars that can be customized to meet individual patient needs is rising. This trend is prompting pharmaceutical companies to explore biosimilar options that align with personalized treatment paradigms. Additionally, the integration of advanced analytics and data-driven insights into biosimilar development is enhancing the ability to create targeted therapies. Consequently, contract manufacturers are likely to adapt their production capabilities to accommodate the growing demand for personalized biosimilars, thereby contributing to the expansion of the Biosimilar Contract Manufacturing Market.

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as diabetes, cancer, and autoimmune disorders is a primary driver for the Biosimilar Contract Manufacturing Market. As these conditions require long-term treatment, the demand for biologics, including biosimilars, is expected to surge. According to recent estimates, the prevalence of chronic diseases is projected to increase significantly, leading to a heightened need for affordable treatment options. This trend is likely to encourage pharmaceutical companies to invest in biosimilar development and contract manufacturing, as they seek to provide cost-effective alternatives to expensive biologic therapies. Consequently, the Biosimilar Contract Manufacturing Market is poised for growth as manufacturers align their capabilities to meet the increasing demand for biosimilars that address chronic health issues.

Technological Advancements in Manufacturing Processes

Technological advancements in biomanufacturing processes are transforming the Biosimilar Contract Manufacturing Market. Innovations such as single-use technologies, continuous manufacturing, and improved cell culture techniques are enhancing production efficiency and reducing costs. These advancements enable contract manufacturers to produce biosimilars at a larger scale while maintaining quality and compliance with regulatory standards. As technology continues to evolve, it is expected that the capabilities of contract manufacturers will expand, allowing for the development of a wider range of biosimilars. This trend is likely to attract more pharmaceutical companies to partner with contract manufacturers, further propelling the growth of the Biosimilar Contract Manufacturing Market.

Market Segment Insights

By Product: Recombinant Glycosylated Proteins (Largest) vs. Recombinant Non-glycosylated Proteins (Fastest-Growing)

The market for biosimilars is significantly driven by recombinant glycosylated proteins, which hold the largest share due to their wide applications in therapeutic areas, including <a href="https://www.marketresearchfuture.com/reports/oncology-drugs-market-12355">oncology</a> and autoimmune diseases. Their complex structure allows for better functionality, making them preferable for a variety of treatments. In contrast, recombinant non-glycosylated proteins are witnessing rapid adoption, particularly in the fields of hormone therapy and enzyme replacements, showcasing their growing relevance in the market.

Biologics: Recombinant Glycosylated Proteins (Dominant) vs. Recombinant Non-glycosylated Proteins (Emerging)

Recombinant glycosylated proteins are the cornerstone of the biosimilar contract manufacturing market, characterized by their intricate structures that facilitate enhanced efficacy in therapeutic applications. This dominance is supported by their established presence in market segments that require high specificity, such as monoclonal antibodies. On the other hand, recombinant non-glycosylated proteins are emerging rapidly, driven by technological advancements in production processes and a growing patient pool requiring reliable therapeutic alternatives. The versatility and adaptability of non-glycosylated proteins are appealing to manufacturers seeking to meet diverse therapeutic needs.

By Production Technology: Mammalian (Largest) vs. Non-Mammalian (Fastest-Growing)

In the Biosimilar Contract Manufacturing Market, the mammalian production technology segment dominates, holding the largest market share due to its wide acceptance and proven efficacy in biopharmaceutical production. This method is preferred for producing complex proteins, offering superior post-translational modifications that are crucial for therapeutic efficacy. On the other hand, non-mammalian systems are rapidly gaining traction as they present cost-effective alternatives, particularly for simpler biosimilars. This diversification points to a market evolution where companies are expanding their technology capabilities. Growth trends indicate that as the demand for biosimilars rises globally, the need for efficient and scalable production methods becomes paramount. The mammalian segment is likely to continue its dominance, while advancements in non-mammalian technologies, such as yeast and bacterial systems, are expected to accelerate growth. Factors driving this shift include increasing regulatory approvals for non-mammalian products and advancements in genetic engineering that enhance yield and productivity. As companies strive for innovation and cost reduction, both segments will play critical roles in shaping the future of biosimilar manufacturing.

Production Technology: Mammalian (Dominant) vs. Non-Mammalian (Emerging)

Mammalian production technology remains the dominant force in the Biosimilar Contract Manufacturing Market due to its ability to produce highly similar biologics that meet stringent regulatory standards. This segment benefits from established processes and infrastructure, making it the preferred choice for developers focusing on complex therapeutic proteins. In contrast, non-mammalian technologies, including microbial systems, are emerging as viable alternatives, especially for less complex biosimilars. These systems often boast faster production times and lower costs, appealing to companies aiming for agility and efficiency. As research progresses, enhancements in non-mammalian methods are likely to bridge the efficacy gap, thus reshaping the competitive landscape and allowing both production types to coexist and thrive.

By Application: Oncology (Largest) vs. Blood Disorders (Fastest-Growing)

The Biosimilar Contract Manufacturing Market is witnessing a diverse distribution of market share across its application segments. Oncology stands out as the largest segment, accounting for a significant portion of the overall market. This dominance is largely attributed to the rising prevalence of cancer and the increasing demand for effective treatment options. In contrast, the Blood Disorders segment, while smaller in market share, is rapidly gaining traction in the industry, driven by advancements in manufacturing processes and a growing patient population requiring these therapies. Growth trends within this market segment indicate a robust increase in both segments. Oncology is propelled by heightened investment in oncology research and development, as well as successful outcomes of biosimilars in clinical settings. Meanwhile, the Blood Disorders market is characterized by continuous innovations and a surge in regulatory approvals, positioning it as the fastest-growing area within the sector as more patients are diagnosed and treated for various blood-related conditions.

Oncology (Dominant) vs. Blood Disorders (Emerging)

Oncology is currently the dominant application in the Biosimilar Contract Manufacturing Market, characterized by a vast array of biosimilars that are essential for the treatment of various cancers. Its prevalence is supported by ongoing research that aims to enhance the effectiveness of these therapies, alongside growing global cancer prevalence. The segment's strong foothold is further reinforced through extensive collaborations between pharmaceutical companies and manufacturers aiming to streamline production and reduce costs. On the other hand, Blood Disorders represent an emerging application, focusing on a smaller yet rapidly expanding market. It benefits from innovative manufacturing techniques and the increasing need for therapies addressing hematological conditions, including anemia and hemophilia. The biosimilars developed for these disorders are critical due to their ability to offer cost-effective alternatives to expensive biologics, driving their growth trajectory.

Get more detailed insights about Biosimilar Contract Manufacturing Market Research Report—Global Forecast till 2035

Regional Insights

North America : Leading Innovation and Demand

North America is the largest market for biosimilar contract manufacturing, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, increasing adoption of biosimilars, and supportive regulatory frameworks. The demand is driven by rising healthcare costs and the need for affordable biologics, with the FDA actively promoting biosimilar approvals to enhance competition and patient access. The United States is the primary player in this market, with significant contributions from companies like Amgen and Catalent. Canada also plays a role, albeit smaller, in the biosimilars landscape. The competitive environment is characterized by the presence of major players such as Samsung Biologics and Lonza Group, which are expanding their manufacturing capabilities to meet the growing demand for biosimilars in the region.

Europe : Regulatory Support and Growth

Europe is the second-largest market for biosimilar contract manufacturing, accounting for approximately 35% of the global market share. The region's growth is fueled by a robust regulatory framework that encourages the development and approval of biosimilars, alongside increasing healthcare costs and a rising demand for affordable treatment options. The European Medicines Agency (EMA) has been instrumental in streamlining the approval process, which has led to a surge in biosimilar products entering the market. Leading countries in this region include Germany, the UK, and France, which are home to several key players like Boehringer Ingelheim and Sandoz. The competitive landscape is marked by a mix of established pharmaceutical companies and emerging biotech firms, all vying for a share of the growing biosimilars market. The presence of strong manufacturing capabilities and innovation in bioprocessing technologies further enhances Europe's position in the global biosimilar landscape.

Asia-Pacific : Emerging Market Potential

Asia-Pacific is rapidly emerging as a significant player in the biosimilar contract manufacturing market, holding approximately 15% of the global market share. The region's growth is driven by increasing healthcare expenditures, a large patient population, and a growing acceptance of biosimilars. Countries like China and India are leading this trend, supported by favorable government policies aimed at boosting local manufacturing and reducing healthcare costs. China is the largest market in the region, with companies like Wuxi Biologics and Fujifilm Diosynth Biotechnologies leading the charge. India is also making strides with its robust pharmaceutical sector, focusing on biosimilars to cater to both domestic and international markets. The competitive landscape is evolving, with both local and international players investing in advanced manufacturing technologies to enhance production efficiency and quality.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually developing its biosimilar contract manufacturing market, currently holding about 5% of the global market share. The growth is primarily driven by increasing healthcare needs, rising awareness of biosimilars, and government initiatives aimed at improving healthcare access. Countries like South Africa and the UAE are at the forefront, with efforts to establish local manufacturing capabilities and attract foreign investment in the biosimilars sector. The competitive landscape is still in its infancy, with a few local players and international companies exploring opportunities in the region. The presence of key players is limited, but there is significant potential for growth as governments focus on enhancing healthcare infrastructure and regulatory frameworks. As the market matures, it is expected to attract more investment and innovation in biosimilar manufacturing.

Key Players and Competitive Insights

The Biosimilar Contract Manufacturing Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for cost-effective biologics and the growing acceptance of biosimilars across various therapeutic areas. Key players such as Samsung Biologics (South Korea), Lonza Group (Switzerland), and Boehringer Ingelheim (Germany) are strategically positioning themselves through innovation and operational excellence. Samsung Biologics (South Korea) has focused on expanding its manufacturing capabilities, while Lonza Group (Switzerland) emphasizes partnerships to enhance its service offerings. Boehringer Ingelheim (Germany) is leveraging its extensive experience in biologics to strengthen its market presence, collectively shaping a competitive environment that prioritizes quality and efficiency.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive advancements in technology and operational practices that set industry standards.

In August Samsung Biologics (South Korea) announced the opening of a new state-of-the-art facility aimed at increasing its production capacity for biosimilars. This strategic move is likely to enhance its competitive edge by meeting the rising global demand for biosimilars, thereby positioning the company as a leader in the contract manufacturing space. The facility is expected to incorporate advanced technologies that streamline production processes, further solidifying Samsung's reputation for quality and reliability.

In September Lonza Group (Switzerland) entered into a strategic partnership with a leading biopharmaceutical company to co-develop a new biosimilar product. This collaboration underscores Lonza's commitment to innovation and its ability to leverage external expertise to accelerate product development. Such partnerships are indicative of a broader trend in the industry, where collaboration is becoming essential for navigating the complexities of biosimilar development and manufacturing.

In July Boehringer Ingelheim (Germany) launched a new initiative focused on sustainability in its manufacturing processes. This initiative aims to reduce the environmental impact of biosimilar production, aligning with global sustainability goals. By prioritizing eco-friendly practices, Boehringer Ingelheim not only enhances its corporate responsibility but also appeals to a growing segment of environmentally conscious consumers and stakeholders.

As of October the competitive trends in the Biosimilar Contract Manufacturing Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in manufacturing processes. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and sustainable practices, reflecting the industry's shift towards a more holistic approach to value creation.

Key Companies in the Biosimilar Contract Manufacturing Market include

Industry Developments

September 2022 Ropidoxuridine, the company's principal clinical sensitizer drug candidate, will be manufactured by Shuttle Pharmaceuticals Holdings Inc. in accordance with a contract with TCG GreenChem, Inc. This drug will be used in the formulation of a drug product that will be tested in clinical studies of Ropidoxuridine and RT of malignancies.

Future Outlook

Biosimilar Contract Manufacturing Market Future Outlook

The Biosimilar Contract Manufacturing Market is projected to grow at an 18.9% CAGR from 2025 to 2035, driven by increasing demand for cost-effective biologics and regulatory support.

New opportunities lie in:

Expansion into emerging markets with tailored biosimilar solutions.</p><p>Investment in advanced bioprocessing technologies for efficiency.</p><p>Strategic partnerships with biotech firms for co-development initiatives.

By 2035, the market is expected to solidify its position as a leader in biopharmaceutical manufacturing.

Market Segmentation

Biosimilar Contract Manufacturing Market Product Outlook

Recombinant Non-glycosylated Proteins
Recombinant Glycosylated Proteins

Biosimilar Contract Manufacturing Market Application Outlook

Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic & Autoimmune Disorders
Rheumatoid Arthritis
Others

Biosimilar Contract Manufacturing Market Production Technology Outlook

Mammalian
Non-Mammalian

Report Scope

MARKET SIZE 2024	7.729(USD Billion)
MARKET SIZE 2025	9.189(USD Billion)
MARKET SIZE 2035	51.9(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	18.9% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Roche (CH), Amgen (US), Sandoz (CH)
Segments Covered	Product, Production Technology, Application, Region
Key Market Opportunities	Growing demand for cost-effective biologics drives expansion in the Biosimilar Contract Manufacturing Market.
Key Market Dynamics	Rising demand for cost-effective biologics drives competition among biosimilar contract manufacturers amid evolving regulatory landscapes.
Countries Covered	North America, Europe, APAC, South America, MEA